- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Raymond James startet Coverage für Aardvark Therapeutics mit "Strong Buy" und hohem Kurspotenzial | 5 | Investing.com Deutsch | ||
| Di | Raymond James initiates coverage on Aardvark Therapeutics stock with Strong Buy | 3 | Investing.com | ||
| 14.11. | Stifel reiterates Buy rating on Aardvark Therapeutics stock, maintains $24 target | 1 | Investing.com | ||
| 14.11. | Aardvark Therapeutics stock price target lowered to $18 at RBC Capital | 1 | Investing.com | ||
| 13.11. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates | 237 | GlobeNewswire (Europe) | Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associated... ► Artikel lesen | |
| AARDVARK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Aardvark Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) | 3 | GlobeNewswire (USA) | ||
| 07.11. | BTIG stuft Aardvark Therapeutics mit "Buy" ein und sieht deutliches Kurspotenzial | 2 | Investing.com Deutsch | ||
| 07.11. | BTIG initiates coverage on Aardvark Therapeutics stock with Buy rating | 1 | Investing.com | ||
| 04.11. | Aardvark Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 04.11. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025 | 1 | GlobeNewswire (USA) | ||
| 04.11. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | 2 | GlobeNewswire (USA) | ||
| 17.10. | Aardvark Therapeutics Expands Phase 3 HERO Trial Eligibility for ARD-101 in Prader-Willi Syndrome After FDA Protocol Alignment | 1 | Insider Monkey | ||
| 30.09. | Jones Trading initiates coverage on Aardvark Therapeutics stock with Buy rating | 2 | Investing.com | ||
| 23.09. | Aardvark Therapeutics, Inc.: Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum | 2 | GlobeNewswire (USA) | ||
| 23.09. | H.C. Wainwright reiterates Buy rating on Aardvark Therapeutics stock | 1 | Investing.com | ||
| 21.08. | Cantor Fitzgerald bestätigt "Overweight"-Rating für Aardvark Therapeutics und sieht über 400 % Kurspotenzial | 4 | Investing.com Deutsch | ||
| 21.08. | Cantor Fitzgerald reiterates Overweight rating on Aardvark Therapeutics stock | 2 | Investing.com | ||
| 14.08. | Cantor Fitzgerald: Erfolgschancen der Phase-3-Studie von Aardvark Therapeutics massiv unterbewertet | 8 | Investing.com Deutsch |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 247,99 | +30,54 % | Morning Market Movers: SMX, Praxis Precision Medicines, Polyrizon, Rubrik, Inc. See Big Swings | HONG KONG (dpa-AFX) - At 7:50 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,900 | +5,37 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| COGENT BIOSCIENCES | 38,770 | -1,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) | ||
| ARCUTIS BIOTHERAPEUTICS | 31,200 | +0,13 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| NUVALENT | 109,60 | +2,56 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,63 | +0,13 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| QIAGEN | 40,405 | -0,02 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,850 | -1,29 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,710 | -4,27 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 76,75 | +1,66 % | Apogee Therapeutics: Noch ein sharedealsPlus-Verdoppler! | Im Juli hatten wir mit der Aktie von Apogee Therapeutics einen Verdopplungskandidaten identifiziert. Jetzt, keine fünf Monate später, konnte die Aktie tatsächlich mehr als +100% zulegen. Ein weiterer... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 38,500 | -1,05 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| TREVI THERAPEUTICS | 13,470 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| CG ONCOLOGY | 43,300 | -3,20 % | CG Oncology Inc.: New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer | ||
| HARMONY BIOSCIENCES | 39,830 | +4,13 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright after positive trial data | ||
| IMMUNOVANT | 22,840 | -0,31 % | Immunovant Inc.: Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients | First-ever potentially disease-modifying therapy for uncontrolled Graves' disease patientsOf 21 patients who entered the six-month off-treatment follow-up period, ~80% (17/21) demonstrated response... ► Artikel lesen |
Das Unternehmen AARDVARK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +9,35 % bei einem Aktienkurs von 13,560 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AARDVARK THERAPEUTICS INC finden Sie auf Wallstreet Online.